Health

Results: 8341-8352 of 8666

PR Newswire associated0

Aidoc Expands its Partnership with GLEAMER to Enhance its Chest Imaging AI Suite

PR Newswire associated0

[Kyoto Asanoha］A challenge from Japan with strict cannabis regulations - Cannafest 2023, Europe's largest cannabis (hemp) expo

Saphetor Partners with ICON to Develop Innovative Data-centric Approach to Precision Medicine Clinical Trial Strategies to Help Support Unique Patients

PR Newswire associated0

EAACI Pediatric Allergy and Asthma Meeting 2023: Shaping the Future of Pediatric Allergy and Asthma Care

MMI Expands Global Footprint with Entry into Asia Pacific Market

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

An illustrative summary of the research outcome with Neu REFIX Beta glucan presents, several “Firsts” to its credit; (1) Oral consumption of a food supplement alone, without any other drugs, reducing skeletal muscle fibrosis in MDX mice, (2) In clinical studies, increase in plasma dystrophin which is considered of relevance to correction of vascular smooth muscle pathology, (3) Clinically evident beneficial reconstitution of gut microbiome in patients with DMD in a 45- days clinical study, (4) Reduction of myocardial fibrosis with neu REFIX alone in MDX mice, (5) Slowing down the progress of DMD pathology evident by 6MWT, NSAA and MRC in a six-month clinical study when Neu REFIX was consumed along with standard of care medication; Neu REFIX 1,3-1,6 Beta glucan is a food supplement without any therapeutic claims; Not a drug or remedy to any illness. Research findings not to be construed as medical advice. Neu REFIX doesn’t contain any of the commonly notified 28 allergens. (Graphic: Business Wire)

Neu REFIX β-glucan reduces muscle fibrosis in Duchenne muscular dystrophy MDX mice, in joint research with Dr. Yoshitsugu Aoki, NCNP, Tokyo, Japan.

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023